Literature DB >> 18773861

Interaction of EGFR 497Arg>Lys with EGF +61A>G polymorphism: modulation of risk in esophageal cancer.

Rohit Upadhyay1, Meenu Jain, Shaleen Kumar, Uday Chand Ghoshal, Balraj Mittal.   

Abstract

Genetic polymorphisms in EGFR 497Arg>Lys and EGF +61A>G genes influence cell cycle progression, apoptosis, angiogenesis, and metastasis. Therefore, we assessed association of esophageal cancer (EC), its clinical characteristics, and environmental interactions with these polymorphisms in 174 patients with EC and 196 controls. No association of EGFR 497Arg/Arg genotype was observed (OR 1.48, p = 0.067) but EGF +61A/A genotype was significantly associated with risk of EC (OR 1.65, p = 0.025), particularly in males (OR 1.76, p = 0.031). Patients with EGF +61A/A genotype were at risk for squamous cell carcinoma (SCC) (OR 1.70, p = 0.021) and tumor at upper anatomical location (OR 3.11, p = 0.009). Interaction of EGF or EGFR genotypes with environmental exposure did not modulate EC risk. However, in gene-gene interaction, EGFR 497Arg/Arg*EGF +61A/A showed significant risk for EC (OR 2.47, p = 0.011). In conclusion, EGF +61A>G gene polymorphisms influenced EC susceptibility and its clinical characteristics. Gene-gene interaction of EGFR 497Arg>Lys and EGF +61A>G polymorphisms enhanced risk for EC, indicating additive effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18773861     DOI: 10.3727/096504008785114147

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  6 in total

1.  Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma risk.

Authors:  Winson Y Cheung; Rihong Zhai; Matthew H Kulke; Rebecca S Heist; Kofi Asomaning; Clement Ma; Zhaoxi Wang; Li Su; Michael Lanuti; Kenneth K Tanabe; David C Christiani; Geoffrey Liu
Journal:  Carcinogenesis       Date:  2009-06-11       Impact factor: 4.944

2.  Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action.

Authors:  Yaping Xu; Liming Sheng; Weimin Mao
Journal:  Oncol Lett       Date:  2012-10-24       Impact factor: 2.967

3.  Association between EGF promoter polymorphisms and cancer risk: a meta-analysis.

Authors:  Wei Xu; Yan Li; Xueli Wang; Bo Chen; Shan Liu; Yan Wang; Weihong Zhao; Jianqing Wu
Journal:  Med Oncol       Date:  2009-12-24       Impact factor: 3.064

4.  Genetic variation in the EGFR gene and the risk of glioma in a Chinese Han population.

Authors:  Wu-Gang Hou; Wen-Bo Ai; Xiao-Guang Bai; Hai-Long Dong; Zhen Li; Yuan-Qiang Zhang; Li-Ze Xiong
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

5.  Lack of Association between Epidermal Growth Factor or Its Receptor and Reflux Esophagitis, Barrett's Esophagus, and Esophageal Adenocarcinoma: A Case-Control Study.

Authors:  Tereza Deissova; Michaela Cvanova; Zdenek Kala; Zuzana Jiraskova Zakostelska; Jiri Dolina; Lumir Kunovsky; Radek Kroupa; Zdenek Pavlovsky; Bretislav Lipovy; Zdenek Danek; Lydie Izakovicova Holla; Ondrej Urban; Vit Navratil; Robert Lischke; Tomas Harustiak; Tomas Grolich; Vladimir Prochazka; Ondrej Slaby; Petra Borilova Linhartova
Journal:  Dis Markers       Date:  2022-08-31       Impact factor: 3.464

6.  Genetic variants of EGF and VEGF predict prognosis of patients with advanced esophageal squamous cell carcinoma.

Authors:  Pei-Wen Yang; Min-Shu Hsieh; Ya-Chuan Huang; Ching-Yueh Hsieh; Tzu-Hsuan Chiang; Jang-Ming Lee
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.